River Global Investors Slashes MaxCyte Stake from 6.1% to 0.8% After Fund Transfer
MXCT sits 65% above its 52-week low of $0.643 on light trading volume (0.3× avg).
Summary
River Global Investors LLP has cut its MaxCyte stake from 6.1% to 0.8% after transferring funds to Liontrust Investment Partners LLP following a parent-company acquisition. The move removes a significant institutional holder and involved net sales of over 800,000 shares in recent months.
Key Events · Ownership and Investor Activity · MXCT
-
Stake Slashed to 0.8%
River Global Investors LLP reduced its beneficial ownership from 6.1% (previously disclosed May 14, 2026) to 0.8% as of July 31, 2026, following the transfer of funds to Liontrust Investment Partners LLP.
-
Fund Transfer Drives Exit
The FCA approved the acquisition of River Global Holdings Limited, resulting in Liontrust Investment Partners assuming responsibility for River Global's ICVC and ICAV funds, which held approximately 4.3% of MaxCyte's voting rights.
-
Net Selling of ~830K Shares
Between May 20 and July 29, 2026, River Global executed net sales of roughly 830,000 shares at prices between $0.99 and $1.13, with the largest blocks sold on July 27–29.
-
Remaining Stake to Be Transferred
The residual 0.8% stake (834,100 shares) will be transferred to Liontrust at a later stage, completing the exit.
Analysis · MXCT · Industrial Applications And Services
River Global Investors LLP, which disclosed a 6.1% stake in MaxCyte in May 2026, has reduced its holding to just 0.8% following the FCA-approved acquisition of its parent company by Liontrust. The bulk of the shares—approximately 4.3% of MaxCyte's outstanding equity—were transferred to Liontrust Investment Partners LLP as part of the deal, with the remaining 0.8% to be transferred later. The filing details net sales of over 800,000 shares between June and July at prices ranging from $0.99 to $1.13, representing a significant exit by a previously notable institutional holder. While the reduction is driven by corporate restructuring rather than a fundamental view on MaxCyte, the loss of a 6%+ shareholder and the associated selling pressure are notable for a micro-cap stock.
At the time of this filing, MXCT was trading at $1.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $114.6M. The 52-week trading range was $0.64 to $2.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.